Articles > Popular publications > PR Newswire press releases > July-September 2009 > Friday, September 25

Article: Afinitor(R) (everolimus) Now Licensed in UK for Advanced Kidney Cancer Patients After Failure of First Line Vascular Targeted Therapy(1, 2).

Article from:
PR Newswire
Article date:
September 25, 2009
Copyright

FRIMLEY, England, September 25 /PRNewswire/ -- 

 
  - This Press Release is Intended for Consumer Media Only 
 
  - Afinitor More Than Doubles the Median Time Without Tumour Growth and 
  Reduces the Risk of Disease Worsening or Death by 67% Compared With 
  Placebo (2) 
 
  - Patients With Advanced Kidney Cancer Have Limited Options Once Tumours 
  Progress After First Line Standard Therapy(3) 
 
  - Recently Published UK Expert Clinical Consensus Recommend 
  Afinitor as Second-Line Therapy for Advanced Kidney Cancer Based on 
  Class I Evidence(4)

Afinitor(R) (everolimus) has recently been licensed for the treatment of advanced kidney cancer after ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: RAD001 More Than Doubles Time Without Tumour Growth After Failure ...
PR Newswire Europe;  May 27, 2008 ;     700+ words ... ... option for patients with advanced kidney cancer who have failed standard ... demonstrated clinical benefit in advanced kidney cancer patients who have experienced ... Hanlon, Kidney Cancer UK. "Advanced kidney cancer is especially difficult ...

Article: FDA approves new treatment for advanced kidney ...
M2 Presswire;  December 21, 2005 ;     614 words ... ... approves new treatment for advanced kidney cancer(C)1994-2005 M2 COMMUNICATIONS ... approval of Nexavar to treat advanced kidney cancer brings a much needed option ... studies in patients with advanced kidney cancer have shown that patients ...

Article: Cancer drug rule 'overdue' ; A decision to allow patients with ...
Western Morning News, The Plymouth (UK);  February 5, 2009 ;     700+ words ... ... decision to allow patients with advanced kidney cancer to access a new drug is ... The medicines do not cure advanced kidney cancer but they can extend a person ... patients will be diagnosed with advanced kidney cancer and at any one time around ...

Article: Bayer and Onyx Announce Positive Phase II Data in Patients With ...
PR Newswire;  October 25, 2004 ;     700+ words ... ... treatment of patients with advanced kidney cancer utilizing results from the ... in the study, 202 were advanced kidney cancer patients, who had progressing ... enroll over 800 patients with advanced kidney cancer. The primary endpoint of ...

Article: Preliminary Phase 2 Data Suggest ABX-EGF Has Single-Agent ...
Business Wire;  May 21, 2002 ;     700+ words ... ... treatment for patients with advanced kidney cancer. Results from the multi ... this patient group with advanced kidney cancer for whom there is no standard ... options for patients with advanced kidney cancer are very limited. Abgenix ...

Article: Latest RAD001 Study Results Show Further Increase in Time Without ...
PR Newswire Europe;  September 17, 2008 ;     700+ words ... ... daily oral mTOR therapy for advanced kidney cancer New data continue to demonstrate ... everolimus) for patients with advanced kidney cancer who have failed standard ... of time in patients with advanced kidney cancer that progressed despite ...

Article: AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination ...
Business Wire;  November 17, 2009 ;     700+ words ... ... drug, in patients with advanced kidney cancer. Torisel is approved in ... Union for the treatment of advanced kidney cancer. Preliminary results of ... treat cancers such as advanced kidney cancer; toxicities associated ...

Article: Afinitor(R) (everolimus) Now Licensed in UK for Advanced ...
PR Newswire Europe;  September 24, 2009 ;     700+ words ... ... Placebo (2) - Patients With Advanced Kidney Cancer Have Limited Options Once ... Second-Line Therapy for Advanced Kidney Cancer Based on Class I Evidence ... licensed for the treatment of advanced kidney cancer after failure of treatments ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives